 |
 |
|||||
  |
 |
 |
 |
 |
 |
|
 |
|
|
Molecular Medicine -- also known as Personalized Medicine, Genomic Medicine and pharmacogenomics -- uses genome-derived data, including human genetic variation, RNA and protein expression differences, to predict the safety and/or efficacy of drugs in individual patients or groups of patients.
Molecular Medicine is becoming widely acknowledged as a major force for the transformation of healthcare. Following the mapping of the Human Genome, it is becoming practical to identify an individual's molecular make-up, and thereby know his/her particular susceptibility to certain diseases, the probable progression of those diseases, and his/her likely response to certain therapeutics. Thus, physicians are gaining access to a new generation of tools to differentiate among patients at the molecular level, and to individualize diagnosis, prevention, and treatment appropriately. This profound shift will affect the ways in which physicians practice medicine, institutions deliver medical care, third party payers reimburse costs, decision makers develop public health policy, and regulators assess new drugs, as well as how patients perceive medical care. Since Molecular Medicine is so far-reaching, by definition it demands a multi-disciplinary approach to planning and execution of programs. For companies and organizations that are active in this arena, it is essential to address both the challenges and the opportunities with an integration of disciplines that is unprecedented in the life sciences. FKH is helping with that challenge. |
|
||
 |
||||
|
|
|
|
|